Dr. Khuri discusses EGFR-based adv #NSCLC trials: no good reason to add chemo w/EGFR TKI, at least not in someone w/o EGFR mut’n. #ASCO10

Related posts:

Dr. Khuri: why did frail women… Dr. Khuri: why did frail women benefit w/Tarceva & men not? Men should admi...

What’s first line chemo-based … What’s first line chemo-based treatment of choice for a never-smoker with ad...

Article in @NEJM discusses exp… Article in @NEJM discusses exposure to radiation from medical imaging studies ...

PF299804 blocks EGFR< HER2,… PF299804 blocks EGFR< HER2, & HER4 & looks favorable in adv NSCLC c/...

MET & EGFR inhibition are syne… MET & EGFR inhibition are synergistic in #NSCLC cell lines. Makes ARQ-197 wit...